CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...